Trial · NCT00363298

Dextro-Amphetamine Versus Caffeine in Treatment-resistant OCD

NCT00363298, Not applicable, Completed, Stanford University; results first posted 2017-03-28

3 sourcestrials-2026-11-12-0.5.0

Cite this record

ConductScience Library. Dextro-Amphetamine Versus Caffeine in Treatment-resistant OCD. Trials, record NCT00363298. Release trials-2026-11-12-0.5.0, 12 Nov 2026. https://conductscience.org/library/trials/NCT00363298

On this page

Trial

As registered on ClinicalTrials.gov, in the graph's capture of the registry.

Title: Dextro-Amphetamine Versus Caffeine in Treatment-resistant OCD
NCT number: NCT00363298
Status: Completed
Phases: Not applicable
Enrollment: 24 participants, actual
Lead sponsor: Stanford University
Conditions: Obsessive-Compulsive Disorder
Interventions: dextro-amphetamine, Sham Comparison
First posted: 2006-08-15
Last updated: 2017-03-28
Results first posted: 2017-03-28
Limitations and caveats: Modest sample size of 24 subjects, 12 in each drug group. Observation period was only 5 weeks long.

Source ClinicalTrials.gov

Registered outcomes2

Each outcome the trial registered, primary first, in ClinicalTrials.gov's words.

List	Outcome	Time frame	Description
Primary	Number of Subjects With Clinical Global Impressions Scale - Improvement (CGI-I) Score of 1 or 2	At end of week 5, except 1 d-amphetamine subject rated at end of week 2	Clinical Global Impressions Scale Improvement Score = 1 (very much improved), or 2 (much improved). Additional possible scale scores are 3 (minimally improved), 4 (no change), 5 (minimally worse), 6 (much worse) and 7 (very much worse).
Primary	Yale-Brown Obsessive-Compulsive Scale (Y-BOCS) Score	At end of week 5, except 1 d-amphetamine subject rated at end of week 2	Yale-Brown Obsessive-Compulsive Scale score by blinded investigator in direct interview. The scale score is the sum of ten items (5 for obsessions and 5 for compulsions: time occupied, degree of interference with functioning, degree of distress, effort to resist the symptom, success in resisting), each rated from 0 to 4, with higher scores indicating more severe OCD. Maximum score is 40. Scores of 14 and below are often described as "subclinical," though patients with these scores may still exhibit troubling symptoms and mild to moderate distress. A total score of 8 or less is often termed "remission." A decrease in total score from baseline to endpoint of either 25% or 35% is often used as a "responder" criterion in clinical trials.

Source ClinicalTrials.gov

Outcomes2

Each outcome the trial posted results for, in ClinicalTrials.gov's words.

Type	Outcome	Time frame	Population	Units	Measured as
PRIMARY	Number of Subjects With Clinical Global Impressions Scale - Improvement (CGI-I) Score of 1 or 2	At end of week 5, except 1 d-amphetamine subject rated at end of week 2	Subjects who met the study continuation phase entry criterion of \>20% decrease in Y-BOCS score after 1 week of double-blind study medication, and entered this 4-week double-blind continuation phase	participants	NUMBER
PRIMARY	Yale-Brown Obsessive-Compulsive Scale (Y-BOCS) Score	At end of week 5, except 1 d-amphetamine subject rated at end of week 2	Subjects who entered the 4-week double-blind study continuation phase, including a last observation carried forward for the one d-amphetamine subject who dropped out of this phase at the end of study week 2 (end of the first week of the continuation phase) for lack of efficacy.	units on a scale	MEAN

Source ClinicalTrials.gov

Results by group4

Each measurement the trial posted, group by group, in the words and numbers it posted.

Outcome	Group	Value	Spread	Units
Number of Subjects With Clinical Global Impressions Scale - Improvement (CGI-I) Score of 1 or 2	D-amphetamine	6		participants
Number of Subjects With Clinical Global Impressions Scale - Improvement (CGI-I) Score of 1 or 2	Caffeine Pills	7		participants
Yale-Brown Obsessive-Compulsive Scale (Y-BOCS) Score	D-amphetamine	13.3	Standard Deviation 6.9	units on a scale
Yale-Brown Obsessive-Compulsive Scale (Y-BOCS) Score	Caffeine Pills	13.0	Standard Deviation 8.4	units on a scale

Source ClinicalTrials.gov

Participant flow12

How many started, completed or left each group, period by period.

Period	Milestone	Group	Participants
First Study Week	STARTED	D-amphetamine	12
First Study Week	STARTED	Caffeine Pills	12
First Study Week	COMPLETED	D-amphetamine	6
First Study Week	COMPLETED	Caffeine Pills	7
First Study Week	NOT COMPLETED	D-amphetamine	6
First Study Week	NOT COMPLETED	Caffeine Pills	5
4-week Study Continuation Phase	STARTED	D-amphetamine	6
4-week Study Continuation Phase	STARTED	Caffeine Pills	7
4-week Study Continuation Phase	COMPLETED	D-amphetamine	5
4-week Study Continuation Phase	COMPLETED	Caffeine Pills	7

1 to 10 of 12Source ClinicalTrials.gov

See all 12 participant flow

Adverse events14

Each adverse event the trial posted, group by group: the participants affected out of those at risk.

Type	Event	Organ system	Group	Affected	At risk
other	insomnia	Psychiatric disorders	D-amphetamine	2	12
other	insomnia	Psychiatric disorders	Caffeine Pills	2	12
other	dry mouth	Gastrointestinal disorders	D-amphetamine	2	12
other	dry mouth	Gastrointestinal disorders	Caffeine Pills	0	12
other	decreased appetite	Gastrointestinal disorders	D-amphetamine	1	12
other	decreased appetite	Gastrointestinal disorders	Caffeine Pills	0	12
other	nausea	Gastrointestinal disorders	D-amphetamine	0	12
other	nausea	Gastrointestinal disorders	Caffeine Pills	1	12
other	intermittent jitteriness	Nervous system disorders	D-amphetamine	0	12
other	intermittent jitteriness	Nervous system disorders	Caffeine Pills	1	12

1 to 10 of 14Source ClinicalTrials.gov

See all 14 adverse events

Adverse event totals6

The totals the trial posted for each group.

Total	Group	Affected	At risk
Total, all-cause mortality	D-amphetamine
Total, all-cause mortality	Caffeine Pills
Total, other adverse events	D-amphetamine	5	12
Total, other adverse events	Caffeine Pills	4	12
Total, serious adverse events	D-amphetamine	0	12
Total, serious adverse events	Caffeine Pills	0	12

Source ClinicalTrials.gov

Papers1

The papers the trial lists on ClinicalTrials.gov.

PMID	Listed as
19573497	RESULT

Source PubMed

Grants0

The grants NIH RePORTER links to the trial, newest funded first: NIH's, and some of AHRQ's, CDC's, FDA's and VA's. Each shows its title, principal investigators, organization and funder in its newest year.

None in this release.

Trial comparisons2

Comparisons of the trial's two groups, calculated by ConductScience from the counts it posted.

Comparison	Source
D-amphetamine vs Caffeine Pills: Number of Subjects With Clinical Global Impressions Scale - Improvement (CGI-I) Score of 1 or 2	Trial comparisons
D-amphetamine vs Caffeine Pills: serious adverse events	Trial comparisons

Tests0

The ConductCognition tests this trial's registered outcomes name, as ScienceGraph matched them in trial-tests-2026-11-12-0.2.1.

None in this release.

Data dates

The day each source was copied for this release.

ClinicalTrials.gov: 2026-11-12; ClinicalTrials.gov
Results, from AACT: 2026-03-23; AACT
NIH grant links: 2026-11-13; NIH RePORTER

Sources 3

ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
ClinicalTrials.govNo license stated
NIH RePORTER's clinical studies and project filesPublic domain

Each source's terms

ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
ClinicalTrials.govnone stated
NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)

ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.

For software

Read this trial from software.

The record and each of its lists are JSON, twenty rows a page. No key.

GET https://conductscience.org/api/trials/v1/NCT00363298

GET https://conductscience.org/api/trials/v1/NCT00363298/registered

API reference For AI assistants